SG11201806907XA - Obesity risk diagnosis kit and method for analyzing risk of obesity onset - Google Patents

Obesity risk diagnosis kit and method for analyzing risk of obesity onset

Info

Publication number
SG11201806907XA
SG11201806907XA SG11201806907XA SG11201806907XA SG11201806907XA SG 11201806907X A SG11201806907X A SG 11201806907XA SG 11201806907X A SG11201806907X A SG 11201806907XA SG 11201806907X A SG11201806907X A SG 11201806907XA SG 11201806907X A SG11201806907X A SG 11201806907XA
Authority
SG
Singapore
Prior art keywords
obesity
risk
analyzing
onset
diagnosis kit
Prior art date
Application number
SG11201806907XA
Inventor
Satoko ARATANI
Hidetoshi Fujita
Toshihiro Nakajima
Original Assignee
Watahiki Hajime
Toshihiro Nakajima
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Watahiki Hajime, Toshihiro Nakajima filed Critical Watahiki Hajime
Publication of SG11201806907XA publication Critical patent/SG11201806907XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

OBESITY RISK DIAGNOSIS KIT AND METHOD FOR ANALYZING RISK OF OBESITY ONSET To provide an obesity risk diagnosis kit and a method for analyzing the risk of obesity onset. An obesity risk diagnosis kit including a probe for analyzing genetic information of an obese person and a non-obese person and identifying a synoviolin gene as an obesity marker by utilizing elevated expression of the synoviolin gene in the obese person. A method for analyzing the risk of obesity onset, including a step for measuring the expression level of the synoviolin gene in a sample collected from a subject organism, and a step for determining the risk of obesity onset using the expression level of the synoviolin gene.
SG11201806907XA 2016-03-15 2017-03-13 Obesity risk diagnosis kit and method for analyzing risk of obesity onset SG11201806907XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016051038 2016-03-15
PCT/JP2017/009903 WO2017159592A1 (en) 2016-03-15 2017-03-13 Obesity risk diagnosis kit and method for analyzing risk of obesity onset

Publications (1)

Publication Number Publication Date
SG11201806907XA true SG11201806907XA (en) 2018-09-27

Family

ID=59851484

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201806907XA SG11201806907XA (en) 2016-03-15 2017-03-13 Obesity risk diagnosis kit and method for analyzing risk of obesity onset

Country Status (8)

Country Link
US (1) US20190078074A1 (en)
EP (1) EP3431594A1 (en)
JP (1) JPWO2017159592A1 (en)
CN (1) CN108779454A (en)
AU (1) AU2017234903A1 (en)
CA (1) CA3014526A1 (en)
SG (1) SG11201806907XA (en)
WO (1) WO2017159592A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1666607A4 (en) * 2003-07-31 2007-11-21 Banyu Pharma Co Ltd METHOD OF EVALUATING COMPOUND EFFICACIOUS IN TREATING OBESITY BY USING Slc25a10
JP5804599B2 (en) * 2009-05-13 2015-11-04 国立研究開発法人理化学研究所 Visceral fat type obesity test drug and its use
US20130143748A1 (en) * 2010-05-27 2013-06-06 Sekisui Medical Co., Ltd. Methods for detection of risk of obesity and risk of onset of diabetes
JP6230546B2 (en) * 2012-12-26 2017-11-15 中島　利博 Method for screening compound having preventive and therapeutic action for obesity

Also Published As

Publication number Publication date
CN108779454A (en) 2018-11-09
CA3014526A1 (en) 2017-09-21
WO2017159592A1 (en) 2017-09-21
US20190078074A1 (en) 2019-03-14
EP3431594A1 (en) 2019-01-23
AU2017234903A1 (en) 2018-08-30
JPWO2017159592A1 (en) 2019-03-28

Similar Documents

Publication Publication Date Title
MX2015016047A (en) Method and system for maintaining or improving wellness.
ATE554389T1 (en) APEX AS A MARKER FOR LUNG CANCER
GB2488700B (en) Methods for monitoring disease conditions by analysis of the full repertoire of CDR3 sequences of an individual
EP3816303A3 (en) Breast cancer detection kit or device, and method for detecting breast cancer
NZ607282A (en) Method for using gene expression to determine prognosis of prostate cancer
EP3800253A3 (en) Prostate cancer detection kit or device, and detection method
EP4219765A3 (en) Prostate cancer prognosis using biomarkers
WO2014140933A8 (en) Method for the prognosis and treatment of cancer metastasis
MX2016003368A (en) Image analysis techniques for diagnosing diseases.
SG11201811263WA (en) Molecular marker, reference gene, and application and test kit thereof, and method for constructing testing model
HK1115636A1 (en) Use of cyfra 21-1 as a marker for colorectal cancer cyfra 21-1
WO2018007872A9 (en) Biomarkers for inflammatory bowel disease
WO2015131151A3 (en) Method and apparatus for determining markers of health by analysis of blood
MX2021012347A (en) Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm.
WO2015034886A3 (en) Wellness panel for companion animals
MX2018001697A (en) Method for the quantification of faecalibacterium prausnitzii phylogroup i and/or phylogroup ii members and the use thereof as biomarkers.
EA201490946A1 (en) METHOD OF QUANTITATIVE EVALUATION OF CANCER TREATMENT
EP2977467A3 (en) Method, use of marker, and determination device for obtaining information on plural types of cancers
MX2017014196A (en) Detection of oral microbial virulence factors.
EP3495502A3 (en) Biomarkers for premature birth
WO2009149319A3 (en) Gene expression profiles associated with asthma exacerbation attacks
BR112016028838A2 (en) antibodies, nucleic acid, host cell, antibody production method, immunoconjugate, pharmaceutical formulation, methods of detecting human lgr5 in a biological sample, detecting a cancer, identifying a cancer patient, selecting a patient with cancer for treatment with an immunoconjugate and treatment of a cancer patient
MX359376B (en) Method and kit for determination of free copper in serum.
MX2016012278A (en) Early detection of preeclampsia.
ATE468535T1 (en) USE OF NNMT AS A MARKER FOR LUNG CANCER